In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species
Denning, D.W.; Hanson, L.H.; Stevens, D.A.
European Journal of Clinical Microbiology and Infectious Diseases Official Publication of the European Society of Clinical Microbiology 9(9): 693-697
ISSN/ISBN: 0934-9723 PMID: 2171940 DOI: 10.1007/bf01964275
Twenty isolates of aspergillus was tested against saperconazole and 16 of these against itraconazole and amphotericin B using a macrodilution broth method. For 18 (90%) of 20 isolates tested against saperconazole, MICs were .ltoreq. 3.1 mg/l and for 15 (75%) of 20 isolates MFCs were .ltoreq. 3.1 mg/l. For 9 (56%) of 16 isolates tested against itraconazole, MICs were .ltoreq. 3.1 mg/l, and for 4 (33%) of 12 isolates MFCs were .ltoreq. 3.1 mg/l. For all 16 isolates tested against amphotericin B MICs and MFCs were .ltoreq. 4.0 mg/l; for 11 of 16 isolated MICs were .ltoreq. 2.0 mg/l. Saperconazole appears to be highly active against Aspergillus spp. in vitro, with a bimodal distribution of MICs and MFCs.